Novel hepatocyte-like liver organoids recapitulate crucial mature hepatic functions

Arif I. Ardisasmita,Indi P. Joore,Natacha Levy,Adam Myszczyszyn,Ary Marsee,Theo Sinnige,Jos Ruiter,Sacha Ferdinandusse,Oksana Dudaryeva,Elisa Gruber,Valerie Daive,Riccardo Levato,Bart Spee,Monique Verstegen,Luc J.W. van der Laan,Edward E.S. Nieuwenhuis,Imre F. Schene,Sabine Fuchs

DOI: https://doi.org/10.1101/2024.10.29.620824

2024-10-29

Abstract:Accurate liver disease modeling and drug toxicity testing still remain challenging as liver cells in vitro poorly resemble adult hepatocytes, as we previously demonstrated using whole transcriptome and cell identity analysis. To address this, we used our insights into hepatic modeling to develop hepatocyte-like liver organoids (HeLLOs), a novel human organoid model with mature hepatocyte functions superior to existing models. HeLLOs are easily established from (small) healthy or diseased liver tissues and rapidly expanded for an extended period in optimized culture conditions. Transcriptomic and functional analyses revealed that differentiated HeLLOs closely resemble fresh primary human hepatocytes (PHHs) and perform key hepatic functions such as gluconeogenesis, drug metabolism, and bile acid synthesis. We developed a HeLLO-based toxicity assay with higher sensitivity in predicting liver toxicity of known liver-toxic drugs compared to the gold-standard PHHs. By modeling disease-related mechanisms, such as bile acid transport, HeLLOs uncover transport-inhibition toxicity mechanisms of known liver toxic drugs. Single cell sequencing analysis of HeLLOs identified a heterogeneous cluster of cells with cholangiocyte-like and hepatocyte-like cells, overall resembling liver regenerative cells. As such, HeLLOs hold great promise for advancing liver disease modeling and drug testing. To our knowledge, HeLLOs are the best expandable liver model for predicting adverse drug reactions as well as modeling various liver disease mechanisms.

Cell Biology